PPARG and Alzheimer disease: This constitutes a potential advantage of PFV technology in scenarios requiring expression localized to the hippocampus, such as in the recent correction of an Alzheimer’s disease model by LV-mediated peroxisome proliferator-activated receptor gamma (PPARγ) coactivator 1α gene transfer.62